Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.
Abstract: Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.
Abstract: The invention includes methods, kits, and pharmaceutical compositions for enhancing liver regeneration in a mammal in need thereof, comprising administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity. The methods may include administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity and a sirtuin 1 (Sirt1) agonist. The agent that increases NAD activity may be a NAD precursor. The NAD precursor may include one or more of tryptophan, nicotinic acid, nicotinic acid riboside, nicotinamide riboside (NR), nicotinamide, NADP, and NAD itself, and a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 26, 2021
Date of Patent:
January 24, 2023
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
Abstract: The invention refers to new methods for treating spontaneous tumors in humans of the Central Nervous System, more particularly of 3rd and 4th grade tumors, even more particularly gliomas, and is related to the administration of compositions comprising therapeutically effective amounts of resveratrolosides and curcumins, in particular natural extracts comprising said two components. The invention also relates to the realization of pharmaceutical and nutraceutleal compositions comprising resveratrolosides and curcumins More specifically, the invention relates to compositions formulated for the release of active components for sublingual administration.
Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity in a human. The invention also relates to a synthetic composition for use, comprising one or more of said HMOs. The invention further relates to a method for reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity by administering at least one HMO and the use of said one or more HMOs in a dietary management of a human.
Type:
Grant
Filed:
November 2, 2018
Date of Patent:
January 3, 2023
Assignee:
Glycom A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs, Ingvild Dybdrodt Amundsen
Abstract: The present application relates to a medical hydrogel comprising nanofibrillar cellulose, wherein the hydrogel has a viscosity in the range of 2500-9000 Pa·s and a water retention value in the range of 30-100 g/g. The present application also relates to a method for preparing the medical hydrogel The present application relates to the medical hydrogel for use for treating wounds.
Abstract: The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.
Abstract: The invention relates to methods for modulation of the gut flora and/or for supporting immune system function in animals comprising administration of one or more sophorolipids to an animal in need thereof. Animal feed compositions comprising sophorolipids are also provided.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
December 13, 2022
Assignee:
DSM IP ASSETS B.V.
Inventors:
Christopher Michael Butt, Pietro Celi, Norman Salem
Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
Type:
Grant
Filed:
September 4, 2018
Date of Patent:
December 13, 2022
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Patrick McHugh, Janelle Konietzko
Abstract: This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
December 6, 2022
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Clara Lucia Garcia-Rodenas, Jose Manuel Ramos Nieves, Myriam Sandrine Steinmann
Abstract: Embodiments for the synthesis of sensitive oligonucleotides as well as insensitive oligonucleotides are provided. Sulfur-based groups are used for the protection of exo-amino groups of nucleobases, phosphate groups and 2?—OH groups, and as cleavable linker for linking oligonucleotides to a support. Oligonucleotide syntheses are achieved under typical conditions using phosphoramidite chemistry with important modifications. To prevent replacing sulfur-based protecting groups by acyl groups via cap-exchange, special capping agents are used. To retain hydrophobic tag to assist RP HPLC purification, special phosphoramidites are used in the last synthetic cycle. With the sulfur-based groups for protection and linking, oligonucleotide deprotection and cleavage are achieved via oxidation followed by beta-elimination under mild conditions.
Abstract: Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.
Abstract: A method for making reduction sensitive nano micelles comprising: 1) dissolving taurine in distilled water, and adding sodium hydroxide solution; 2) dissolving acryloyl chloride in dichloromethane, reacting at 25° C.; dissolving lipoic acid in toluene and adding hydroxyethyl methacrylate, reacting at 85° C.; 3) dissolving N-acryloyltaurine and lipoic acid methacryloyloxyethyl ester and reacting at 60˜65° C., dropping the polymer solution into deionized water, adding dithiothreitol and reacting at 25˜30° C. to obtain reduction sensitive nano micelles after freeze-drying. The nano micelles have regular morphology and uniform distribution, and can be used as drug carriers for controlled release.
Type:
Grant
Filed:
December 31, 2020
Date of Patent:
November 29, 2022
Assignee:
JIANGNAN UNIVERSITY
Inventors:
Liping Zhang, Caihua Ni, Xinxin Sang, Gang Shi
Abstract: The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder.
Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
Abstract: An AMP-activated protein kinase (AMPK) activating agent comprises 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-b-D-glucose (“GHG”) as an active ingredient. The AMPK activating agent can be a GHG-containing composition wherein the GHG is an active ingredient of the composition. The GHG-containing composition can be derived from Kenyan purple tea, whose scientific name is Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.
Abstract: Provided in the present invention is the use of a verbascoside in the preparation of a drug for preventing or treating glomerular podocyte injured renal disease, belonging to the field of medicine. The inventors found that the verbascoside can effectively restore the viability of glomerular podocytes, reduce the abnormal migration ability thereof, protect the cytoskeletons of the podocytes, and restore the expression levels of podocyte injury markers, i.e. nephrin protein and synaptopodin protein, thereby significantly reducing urinary protein. Therefore, the verbascoside can be applied to prepare drugs or healthcare products for preventing or treating diseases associated with glomerular podocyte injury, alone or in combination with other drugs, and to prepare drugs or healthcare products for alleviating damage to podocytes caused by other drugs, thereby providing new treatment means and ideas for diseases caused by glomerular podocyte injury.